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PURPOSE: The aim of this study was to evaluate the effect of dexmedetomidine on shivering during spinal
anesthesia.
METHODS: Sixty patients (American Society of Anesthesiologists physical status I or II, aged 18-50 years), scheduled
for elective minor surgical operations under spinal anesthesia with hyperbaric bupivacaine, were enrolled. They
were administered saline (group C, n=30) or dexmedetomidine (group D, n=30). Motor block was assessed using a
Modified Bromage Scale. The presence of shivering was assessed by a blinded observer after the completion of
subarachnoid drug injection.
RESULTS: Hypothermia was observed in 21 patients (70%) in group D and in 20 patients (66.7%) in group C
(p=0.781). Three patients (10%) in group D and 17 patients (56.7%) in group C experienced shivering (p=0.001).
The intensity of shivering was lower in group D than in group C (p=0.001). Time from baseline to onset of shivering
was 10 (5-15) min in group D and 15 (5-45) min in group C (p=0.207).
CONCLUSION: Dexmedetomidine infusion in the perioperative period significantly reduced shivering associated
with spinal anesthesia during minor surgical procedures without any major adverse effect during the perioperative
period. Therefore, we conclude that dexmedetomidine infusion is an effective drug for preventing shivering and
providing sedation in patients during spinal anesthesia.
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INTRODUCTION
Shivering is defined as an involuntary, repetitive activity
of skeletal muscles. The mechanisms of shivering in patients
undergoing surgery are mainly intraoperative heat loss,
increased sympathetic tone, pain, and systemic release of
pyrogens.
1 Spinal anesthesia significantly impairs the
thermoregulation system by inhibiting tonic vasoconstric-
tion, which plays a significant role in temperature regula-
tion.
2 Spinal anesthesia also causes redistribution of core
heat from the trunk (below the block level) to the peripheral
tissues. These two effects predispose patients to hypother-
mia and shivering.
3 The median incidence of shivering
related to regional anesthesia observed in a review of 21
studies is 55%.
1 Shivering increases oxygen consumption,
lactic acidosis, carbon dioxide production, and metabolic
rate by up to 400%.
4,5 Therefore, shivering may cause
problems in patients with low cardiac and pulmonary
reserves. The best way to avoid these intraoperative and
postoperative shivering-induced increases in hemodynamic
and metabolic demands is to prevent shivering in the first
place.
1 Although dexmedetomidine is among several
pharmacological agents used for the treatment of shivering,
its effects on prevention of shivering during central
neuraxial blockade have not been evaluated to date.
Dexmedetomidine is a highly selective a2-adrenoceptor
agonist with potent effects on the central nervous system.
6-8
Henceforth, the aim of this study was to evaluate the effect
of dexmedetomidine on shivering during spinal anesthesia.
MATERIALS AND METHODS
Sixty patients (American Society of Anesthesiologists
physical status I or II, aged 18-50 years), scheduled for
elective minor surgical operations under spinal anesthesia,
were enrolled in the study. Patients with thyroid disease,
Parkinson’s disease, dysautonomia, Raynaud’s syndrome,
cardiopulmonary disease, a history of allergy to the agents
to be used, a need for blood transfusion during surgery, an
initial core temperature .37.5˚Co r,36.5˚C, a known
history of alcohol use, use of sedative-hypnotic agents, use
of vasodilators, or having contraindications to spinal
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1187anesthesia were excluded from the study. The Local Ethics
Committee approved the study protocol, and all subjects
gave written consent to participate. The temperature of the
operating room was maintained at 21˚Ct o2 2 ˚C (measured
by a wall thermometer). Irrigation and i.v. fluids were
administrated at room temperature and given without in-
line warming. All patients were covered with one layer of
surgical drapes over the chest, thighs, and calves during the
operation and then one cotton blanket over the entire body
postoperatively. No other warming device was used. A core
temperature below 36˚C was considered hypothermia.
Before performing spinal anesthesia, each patient received
10 ml kg
-1h
-1 of lactated Ringer’s solution. The infusion rates
were then reduced to 6 ml kg
-1h
-1. Following the guidelines
for asepsis and antisepsis, subarachnoid anesthesia was
instituted at either the L3-4 or L4-5 interspaces. A volume of
3 ml of hyperbaric bupivacaine (MarcaineH Spinal Heavy
0.5%, AstraZeneca, Istanbul, Turkey) was injected using a
25 G Quincke spinal needle (Typo Healthcare, Gasport, UK).
The patients were randomized to one of two groups by
sequentially numbered envelopes, which designated them
to receive saline (group C, n=30) or dexmedetomidine
(group D, n=30). An investigator who was not otherwise
involved in the study prepared syringes containing saline or
dexmedetomidine; thus, the study was double-blinded. Just
after intrathecal injection, all drugs were infused intrave-
nously. Dexmedetomidine (PrecedexH, Meditera, Istanbul,
Turkey) was diluted to a volume of 50 ml (4 mgm l
-1) and
presented as coded syringes by an anesthesiologist. Group
D was given an i.v. bolus of dexmedetomidine 1 mgk g
-1
administered by a syringe pump (Perfuser compact, Braun,
Germany) over a 10-min period followed by an infusion of
0.4 mgk g
-1h
-1 dexmedetomidine during the surgery. Group
C received an equal volume of saline. The infusions were
stopped at the completion of the closure of the skin.
Supplemental oxygen (2 l min
-1) was delivered via a
facemask during the operation. Motor block was assessed
using a modified Bromage scale (0, no motor block; 1, hip
blocked; 2, hip and knee blocked; 3, hip, knee, and, ankle
blocked). Full motor recovery was scored as 0 on the
Bromage scale. Sensorial block was assessed by the pinprick
test. The levels of motor and sensory blockade were
assessed during the intraoperative period. The presence of
shivering was assessed by a blinded observer after the
completion of subarachnoid drug injection. Shivering was
graded on a scale similar to that validated by Tsai and Chu:
4
0=no shivering, 1=piloerection or peripheral vasoconstric-
tion but no visible shivering, 2=muscular activity in only
one muscle group, 3=muscular activity in more than one
muscle group but not generalized, and 4=shivering invol-
ving the whole body. The incidence and severity of
shivering were recorded at 5-min intervals during the
operation and in the recovery room. If scores were three or
greater at 15 minutes after spinal anesthesia, the prophy-
laxis was regarded as ineffective, and 25 mg pethidine was
administered by i.v. Side effects, such as headache, allergy,
hypotension, bradycardia, waist and back pain, sedation
score, total spinal block, and difficulty in micturition,
nausea and vomiting were recorded. If the patient’s heart
rate fell below 50 bpm, 0.5 mg atropine was administered by
i.v. Hypotension was defined as a decrease in the mean
arterial pressure (MAP) of more than 20 % from baseline
(baseline MAP was calculated from three measurements
taken in the ward before surgery). Hypotension was treated
with 10 mg ephedrine via i.v. bolus and then with further
i.v. infusion of lactated Ringer’s solution as required. The
quantity of ephedrine given in each group was recorded. If
patients developed nausea and vomiting, 10 mg metoclo-
pramide was administered through the i.v. Postoperatively,
all patients were monitored, given oxygen via a facemask
and were covered with one layer of drapes and one cotton
blanket. The post-anesthesia care unit temperature was
maintained at 25˚Ct o2 6 ˚C and constant humidity. If
shivering scores were greater than or equal to 3, 25 mg
pethidine was administered through the i.v. The attending
anesthesiologist also assessed the degree of sedation on a 5-
point scale: 1=fully awake and oriented, 2=drowsy,
3=eyes closed but open on command, 4=eyes closed but
open to mild physical stimulation, and 5=eyes closed and
unresponsive to mild physical stimulation.
10
SPSS 11.0 (SPSS Inc., Chicago, IL) was used to analyze all
statistical data. Sample size estimation was based on our
preliminary study to detect shivering in 15% of patients
using the 2-sided t test with alpha=0.05 and a power of
Table 1 - Demographic and intraoperative variables of the subjects - medians and ranges.
Dexmedetomidine
Group
(n=30)
Control
Group
(n=30) p-value
Gender (male/female) 24/6 23/7 0.754
Age (year) 36 (20-50) 37 (20-50) 0.906
Height (cm) 170 (156-188) 173 (153-188) 0.524
Weight (kg) 80 (50-90) 80 (51-90) 0.784
Duration of surgery (minutes) 65 (25-225) 68 (15-150) 0.917
Duration of motor block (minutes) 220 (75-460) 180 (95-430) 0.739
Duration of sensorial block (minutes) 237 (90-470) 212 (100-470) 0.900
Total dose of Dexmedetomidine (mg) 108 (80-160)
Sensory block Onset at T12 pinprick (minutes) 4 (3–5) 4 (3-5)
Motor block Time to grade 3 block (minutes) 3.2 (2-4.5) 3.3 (2-4.7)
Types of operation
Varicose vein 8 9
Umbilical hernia 2 3
Arthroscopy 10 10
Bladder tumor 5 4
Ureterorenoscopy 5 4
There were no significant differences among the groups.
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118880%. Quantitative variables were compared between groups
using Student’s t-test or a Mann-Whitney U-test where
appropriate. Within-group data for core temperature were
analyzed by using repeated-measures analysis of variance
followed by Bonferroni’s post-hoc testing. Within-group
data for heart rate and mean arterial pressure were analyzed
using a Friedman test. Chi-square analysis was used for
comparison of categorical variables. The results are shown
as median (range), mean (¡SD), exact numbers or propor-
tions are expressed as a percentage. p,0.05 was considered
statistically significant.
RESULTS
The two groups were similar regarding age, weight,
height, duration of surgery, duration of motor block, and
duration of sensorial block (Table 1). Hypothermia was
observed in 21 patients (70%) in group D and in 20 patients
(66.7 %) in group C (p=0.781). The core temperature of
patients was not different between the groups during the
intraoperative or postoperative periods (Figure 1). Three
patients (10%) in group D and 17 patients (56.7%) in group
C experienced shivering (p=0.001). One patient had Grade 1
and two patients had Grade 2 shivering in group D. The
intensity of shivering was lower in group D than in group C
(p=0.001), and Grade 4 shivering was not noted in any
patient in either group. Patients’ shivering scores are given
in Table 2. There were no statistically significant differences
for the mean onset times of shivering between groups,
which were 10 (5-15) min in group D and 15 (5-45) min in
group C (p=0.207). However, there were statistically
significant differences for sedation between groups, all
patients in group D and six patients in group C were in
levels 3-5 of sedation (p=0.001). Mean arterial pressures and
hearth rates were lower in group D following the infusion of
dexmedetomidine during the intra and postoperative
periods (Figures 2 and 3). Although five patients in group
C needed meperidine (25 mg, i.v.) to treat shivering, no
patients in group D needed this treatment. Three patients in
group D and one patient in group C were given 0.5 mg
atropine. One patient in group D was given 10 mg
ephedrine by i.v. during the operation. There were no
statistically significant differences for adverse events
between groups (Table 3). Two patients in group D and
one patient in group C had nausea. Two patients in group D
and one patient in group C had difficulty in micturition in
the first 24 hours following spinal anesthesia. During the
one-week follow-up interview, one patient in each group
reported headache with equivocal characteristics of a
postural puncture headache, both of which resolved with
conservative management.
DISCUSSION
We found that dexmedetomidine infusion effectively
decreased the incidence and severity of shivering related to
regional anesthesia during elective minor surgeries. The
exact mechanism of shivering during regional anesthesia has
not been fully established. The possible mechanisms include
cessation of central thermoregulation, internal redistribution
of body heat, and heat loss to the environment.
2,11,12
Redistribution of core temperature during regional anesthe-
sia is typically restricted to the legs, and therefore core
temperature decreases about half as much during regional
anesthesia as during general anesthesia.
11 Vasoconstriction
and shivering are restricted to the upper body during spinal
anesthesia, as they are inhibited below the level of blockade
through sympathetic and somatic neural block.
12 In contrast
to these changes, vasoconstriction and shivering are
restricted to the upper body during spinal anesthesia. The
median incidence of shivering related to neuraxial anesthesia
in the control groups of 21 studies is 55 % (interquartile range
of 40-64%),
1 which is nearly similar to that of the control
group in our study (63.4%). As shivering is a response to
hypothermia, body temperature should be normally main-
tained within the normal limits of 36.5-37.5˚C.
13 Major risk
Figure 1 - Tympanic Core Temperatures. io: intraoperative, po: postoperative, min: minute, The tympanic core temperatures at each
time interval were similar among the groups.
Table 2 - Perioperative shivering scores of the patients.
Shivering score Group D (n=30) Group C (n=30)
0 27* 13
1 17
2 25
3 05
4 00
*p=0.001 (Chi-square test).
*p=0.001 compared with the other groups using the Chi-square test.
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1189factorsinregionalanesthesiafor hypothermiaareaging,level
ofsensoryblock,andtemperaturesoftheoperatingroomand
intravenous solutions.
14 In our study, the temperature of the
operating room was maintained at 21-22˚C, and all fluids and
drugs were at room temperature during the surgery. Various
drugs have been used to treat or prevent postoperative
shivering. However, dexmedetomidine may be a goodchoice
among them because of its dual effects of anti-shivering and
sedation. Pharmacological therapies, such as pethidine,
tramadol, physostigmine, clonidine, ketamine, and magne-
sium, have been used to prevent shivering.
15-17 Although
clonidine has been used safely and effectively to treat
shivering, other drugs, such as urapidil,
14 may not be
appropriate because the incidence of hypotension is high
during spinal anesthesia. Dexmedetomidine, on the other
hand, isa shortactinga2 mimetic withless hypotensive effect
and an added a sedative effect. Meperidine, the most widely
used agent to prevent shivering, may cause nausea and
vomiting as well as respiratory depression during and after
spinal anesthesia.
18 Hypertensive and tachycardic effects of
ketamine have also been reported.
19 The search continues for
drugs that sufficiently improve the tolerance of thermoregu-
lation without simultaneously producing excessive sedation,
respiratory depression, or hemodynamic instability.
Dexmedetomidine is used for the sedation of mechanically
ventilated patients in the intensive care unit. Thus, ithasbeen
rarely used for the prevention of vasoconstriction and
shivering during spinal anesthesia.
8,9,19-22
Dexmedetomidine displays specific and selective a2-
adrenoceptor agonism in the brain and spinal cord. The
responses to activation of these receptors include decreased
sympathetic tone with attenuation of the neuroendocrine
and hemodynamic responses to anesthesia and surgery.
Thus, dexmedetomidine can mediate both the beneficial and
unwanted effects of shivering provoked by hypothermia,
such as increased catecholamine concentrations, oxygen
consumption, blood pressure, and heart rates.
6,23,24
Dexmedetomidine exerts its dual effects while avoiding
vasoconstriction and increasing the level of the shivering
threshold, but meperidine, only increases the shivering
threshold in healthy volunteers.
22,25 In contrast to our
results, Coskuner et al
26 did not observe shivering with
the same dose that we used in our study. Also, Elvan and
colleagues
8 reported that dexmedetomidine infusion during
surgery was effective in the prevention of post-anesthetic
shivering in patients undergoing elective abdominal hyster-
ectomy. Bicer and colleagues
21 found the incidence of
shivering as 15% with dexmedetomidine and 55% with
placebo following general anesthesia. Our results are similar
to their study with the incidences being 10% and 56.7%,
respectively. The lower incidence of shivering in the
dexmedetomidine group may be related to the depression
Figure 2 - Mean Arterial Pressures. MAP: Mean Arterial Pressure, io: intraoperative, po: postoperative, min; minute, Intraoperative and
postoperative mean arterial pressure. +,0.05 when two groups are compared.
Figure 3 - Heart Rates. io: intraoperative, po: postoperative, min; minute, Intraoperative and postoperative heart rate.
+p,0.05 when
two groups are compared,
*p,0.05 compared with baseline value.
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1190of the thermoregulation threshold. A limitation of our study
was that we did not assess different doses of dexmedeto-
midine; further studies are needed to evaluate the effects of
dexmedetomidine with various doses. The hemodynamic
effects of dexmedetomidine are biphasic. When it is
administered through an i.v., it causes hypotension and
bradycardia until central sympathomimetic effect is
achieved, and then it causes moderate decreases in MAP
and HR.
27,28 In our study, the mean arterial pressures were
lower after the start of the infusion especially at 105 and 120
minutes during the surgery. HR was found to be signifi-
cantly lower in the dexmedetomidine group when com-
pared with the control group beginning from the 5
th minute
of infusion until the end of the blockade. Furthermore, while
the incidence of bradycardia was 10% in group D, one
patient developed bradycardia in group C. One of the main
objectives in using sedative agents is that the drug should
not cause respiratory depression. In previous studies, it has
been shown that a2-adrenergic agonists cause no or minimal
respiratory depression.
29,30 None of our patients had
respiratory depression during the operation or in the
recovery room.
In conclusion, dexmedetomidine infusion in the perio-
perative period significantly reduced the shivering asso-
ciated with spinal anesthesia during minor surgical
procedures without any major adverse effects. We therefore
conclude that dexmedetomidine infusion as a good choice
for preventing shivering in patients undergoing spinal
anesthesia.
REFERENCES
1. Crowley LJ, Buggy DJ. Shivering and neuraxial anesthesia. Reg Anesth
Pain Med. 2008;33:241-52.
2. Glosten B, Sessler DI, Faure EA, Karl L, Thisted RA. Central temperature
changes are poorly perceived during epidural anesthesia. Anesthesiology.
1992;77:10-6, doi: 10.1097/00000542-199207000-00003.
3. Ozaki M, Kurz A, Sessler DI, Lenhardt R, Schroeder M, Moayeri A,
Noyes KM, Rotheneder E. Thermoregulatory thresholds during epidural
and spinal anesthesia. Anesthesiology. 1994;8:282:8, doi: 10.1097/
00000542-199408000-00004.
4. Tsai YC, Chu KS. A comparison of tramadol, amitriptyline, and
meperidine for postepidural anesthetic shivering in parturients. Anesth
Analg. 2001;93:1288-92, doi: 10.1097/00000539-200111000-00052.
5. Macintyre PE, Pavlin EG, Dwersteg JF. Effect of meperidine on oxygen
consumption, carbon dioxide production, and respiratory gas exchange
in postanesthesia shivering. Anesth Analg. 1987;66:751, doi: 10.1213/
00000539-198708000-00010.
6. Doze VA, Chen BX, Maze M. Dexmedetomidine produces a hypnotic-
anesthetic action in rats via activation of central alpha-2 adrenoceptors.
Anesthesiology. 1989;71:75-9, doi: 10.1097/00000542-198907000-00014.
7. Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the
selectivity, specificity and potency of medetomidine as an alpha-2
adrenoceptor agonist. Eur J Pharmacol. 1988:150:9-14, doi: 10.1016/0014-
2999(88)90744-3.
8. Elvan EG, Oc ¸ B, Uzun S, Karabulut E, Cos ¸kun F, Aypar U.
Dexmedetomidine and postoperative shivering in patients undergoing
elective abdominal hysterectomy. Eur J Anaesthesiol. 2008;255:357-64,
doi: 10.1017/S0265021507003110.
9. Blaine Easley R, Brady KM, Tobias JD. Dexmedetomidine for the
treatment of postanesthesia shivering in children. Paediatr Anaesth.
2007;174:341-6.
10. Wilson E, David A, MacKenzie N, Grant IS. Sedation during spinal
anaesthesia: comparison of propofol and midazolam. Br J Anaesth.
1990;64:48-52, doi: 10.1093/bja/64.1.48.
11. Matsukawa T, Sessler DI, Sessler AM, Schroeder M, Ozaki M, Kurz A,
Cheng C. Heat flow and distribution during induction of general
anesthesia. Anesthesiology. 1995;82:662-73, doi: 10.1097/00000542-
199503000-00008.
12. Kurz A, Sessler I, Schroeder M, Kurz M. Thermoregulatory response
thresholds during spinal anaesthesia. Anesth Analg. 1993;77:721-6.
13. Buggy DJ, Crossley AW. Thermoregulation, mild perioperative
hypothermia and postanaesthetic shivering. Br J Anaesth. 2000;84:615-28.
14. Witte JD, Sesler DI. Perioperative shivering. Anesthesiology. 2002;96:
467-84, doi: 10.1097/00000542-200202000-00036.
15. Schwarzkopf KR, Hoff H, Hartmann M, Fritz HG. A comparison
between meperidine, clodine and urapidil in the treatment of postanes-
thetic shivering. Anesth Analg. 2001;92:257-60, doi: 10.1097/00000539-
200101000-00051.
16. Lenhardt R, Orhan-Sungur M, Komatsu R, Govinda R, Kasuya Y, Sessler
DI, et al. Suppression of shivering during hypothermia using a novel
drug combination in healthy volunteers. Anesthesiology. 2009;111:110-5,
doi: 10.1097/ALN.0b013e3181a979a3.
17. Alfonsi P, Passard A, Gaude-Joindreau V, Guignard B, Sessler DI,
Chauvin M. Nefopam and alfentanil additively reduce the shivering
threshold in humans whereas nefopam and clonidine do not.
Anesthesiology. 2009;111:102-9, doi: 10.1097/ALN.0b013e3181a979c1.
18. Patel D, Janardhan Y, Merai B, Robalino J, Shevde K. Comparison of
intrathecal meperidine and lidocaine in endoscopic urological proce-
dures. Can J Anaesth. 1990;37:567-70, doi: 10.1007/BF03006327.
19. Sagir O, Gulhas N, Toprak H, Yucel A, Begec Z, Ersoy O. Control of
shivering during regional anaesthesia: prophylactic ketamine and
granisetron. Acta Anaesthesiol Scand. 2007;51:44-9, doi: 10.1111/j.1399-
6576.2006.01196.x.
20. Doufas AG, Lin CM, Suleman MI, Liem EB, Lenhardt R, Morioka N, et al.
Dexmedetomidine and meperidine additively reduce the shivering
threshold in humans. Stroke. 2003;34:1218-23, doi: 10.1161/01.STR.
0000068787.76670.A4.
2 1 .B i c e rC ,E s m a o g l uA ,A k i nA ,B o y a c iA .D e x m e d e t o m i d i n ea n d
meperidine prevent postanaesthetic shivering. Eur J Anaesthesiol.
2006;232:149-53, doi: 10.1017/S0265021505002061.
22. Talke P, Tayefeh F, Sessler DI, Jeffrey R, Noursalehi M, Richardson C.
Dexmedetomidine does not alter the sweating threshold, but comparably
and linearly decreases the vasoconstriction and shivering thresholds.
Anesthesiology.1997;87:835-41, doi: 10.1097/00000542-199710000-00017.
23. Frank SM, Higgins MS, Breslow MJ, Fleisher LA, Gorman RB, Sitzmann
JV, et al. The catecholamine,cortisol, and hemodynamic responses to
mild perioperative hypothermia. Anesthesiology. 1995; 82:83-93, doi: 10.
1097/00000542-199501000-00012.
24. Kurz A, Sessler DI, Narzt E, Bekar A, Lenhardt R, Huemer G.
Postoperative hemodynamic and thermoregulatory consequences of
intraoperative core hypothermia. J Clin Anesth. 1995;7:359-66, doi: 10.
1016/0952-8180(95)00028-G.
25. Erkola O, Korttila K, Aho M, Haasio J, Aantaa R, Kallio A. Comparison of
intramuscular dexmedetomidine and midazolam premedication for
elective abdominal hysterectomy. Anesth Analg. 1994;79:646-53, doi:
10.1213/00000539-199410000-00006.
26. Coskuner I, Tekin M, Kati I, Yagmur C, Elcicek K. Effects of
dexmedetomidine on the duration of anaesthesia and wakefulness in
bupivacaine epidural block. Eur J Anaesthesiol. 2007;24:535-40, doi: 10.
1017/S0265021506002237.
27. Jalonen J, Hynynen M, Kuitunen A, Heikkila ¨ H, Perttila ¨ J, Salmenpera ¨ M,
et al. Dexmederomidine as an anesthetic adjunct in coronary artery
bypass grafting. Anesthesiology. 1997;86:331-45, doi: 10.1097/00000542-
199702000-00009.
28. Ebert TJ, Hall JE, Barney JA. The effects of increasing plasma
concentrations of Dexmedetomidine in humans. Anesthesiology. 2000;
93:382-94, doi: 10.1097/00000542-200008000-00016.
29. Jaakola ML. Dexmedetomidine premedication before intravenous
regional anesthesia in minor outpatient hand surgery. J Clin Anesth.
1994;6:204-11, doi: 10.1016/0952-8180(94)90060-4.
30. Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: a review
of clinical applications. Anesthesiology. 2008;21:457-61.
Table 3 - Patients’ perioperative adverse events.
Adverse events Group D (n=30) Group C (n=30)
Total spinal block 00
Allergy 00
Hypotension 10
Nausea- vomiting 21
Bradycardia 31
Difficulty in micturition 21
Post-punctural headache 11
Back pain 00
There were no significant differences for adverse events between the
groups.
CLINICS 2011;66(7):1187-1191 Dexmedetomidine and Shivering
Usta B et al.
1191